Brigham and Women's Hospital
Labs, Doctors Still Grapple With Patient Recontact Despite Streamlined Variant Reclassification
Premium
Although leading labs have coalesced around the value of protocols for making sure updated variant calls get to patients, strategies still vary and practical challenges remain.
The Industrial Participant Program, part of the Wyss Diagnostics Accelerator, provides a hub for collaboration and guidance to move promising tech forward.
Bio-Techne, Thermo Fisher Scientific to Further Develop, Commercialize Kidney Transplant Rejection Assay
The exosome-based, liquid biopsy assay discriminates between T-cell mediated rejection and antibody mediated rejection to help improve patient outcomes.
Brigham and Women's Hospital Partners With CureDuchenne on Newborn Screening Program
Brigham and Women's will offer at no cost a blood test that detects elevated levels of an enzyme associated with Duchenne muscular dystrophy.
Wyss Institute, Brigham and Women's Hospital Launch Diagnostic Technology Accelerator
Through the accelerator, Brigham and Women's investigators will identify diagnostic challenges that will be matched with technologies created by Wyss engineers.